Xyall secures €7.6M to accelerate MedTech expansion
Eindhoven-based MedTech startup Xyall has raised €7.6 million in fresh funding to drive the global rollout of its automated tissue dissection system, a technology designed to transform how hospitals and laboratories prepare samples for cancer and other complex diagnostics.
The new capital will enable Xyall to scale manufacturing, expand commercial teams in key markets, and deepen collaborations with leading pathology labs. The company positions its platform as a critical bridge between traditional histopathology workflows and modern molecular diagnostics, including next-generation sequencing and advanced genetic testing.
Automating a critical step in cancer diagnostics
Today, tissue dissection in pathology labs is often a manual, labor-intensive process that can introduce variability and delay results. Xyall’s system uses advanced robotics, computer vision, and guided workflows to automate this step, aiming to deliver more consistent tissue selection and higher-quality samples for downstream analysis.
By standardising tissue preparation, the startup targets a key bottleneck in personalised medicine, where oncologists rely on precise molecular data to match patients with targeted therapies. Automated dissection is expected to reduce human error, improve traceability, and support labs facing staffing shortages and rising test volumes.
Global rollout strategy and market potential
The €7.6 million round will support regulatory clearances, market entry in Europe and North America, and integration with major laboratory information systems. Xyall plans to work closely with large hospital networks, contract research organisations, and pharmaceutical partners to validate its technology in high-throughput environments.
With healthcare systems under pressure to deliver faster, more accurate diagnoses, demand for automation in pathology is growing rapidly. By focusing on the niche but critical step of tissue dissection, Xyall aims to become a key infrastructure player in the global shift toward data-driven oncology and precision diagnostics.